Atea Pharmaceuticals (AVIR) FCF Margin (2021)

Atea Pharmaceuticals (AVIR) recorded quarterly FCF Margin of 39.25% in Q4 2021, down 156.97% quarter-over-quarter from 68.89% in Q3 2021.

Atea Pharmaceuticals (AVIR) FCF Margin (2021) Analysis & Trends

Atea Pharmaceuticals' FCF Margin history runs 1 years deep, the most recent figure standing at 39.25% for Q4 2021.

In Q4 2021, FCF Margin changed N/A year-over-year to 39.25%; the TTM figure through Dec 2021 stood at 24.76% (changed N/A YoY), while the FY2021 annual figure was 24.76%, down 63486.0% from the prior year.
FCF Margin was 39.25% for Q4 2021 at Atea Pharmaceuticals, down from 68.89% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 68.89% in Q3 2021 to a low of 39.25% in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-3.98%
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	43.35%
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Atea Pharmaceuticals	347.28 Mn	347.28 Mn	-	-

Download Data